{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:16:27Z","timestamp":1794003387157,"version":"4.8.0"},"reference-count":47,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Pain Management"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1080\/17581869.2024.2421749","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T05:44:48Z","timestamp":1731908688000},"page":"477-486","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":34,"title":["VX-548 in the treatment of acute pain"],"prefix":"10.1080","volume":"14","author":[{"given":"Aaron Yik","family":"Hang Kong","sequence":"first","affiliation":[{"name":"Department of Women's Anesthesia","place":["Singapore"]},{"name":"KK Women's & Children's Hospital","place":["Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hon Sen","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Women's Anesthesia","place":["Singapore"]},{"name":"KK Women's & Children's Hospital","place":["Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6980-1856","authenticated-orcid":false,"given":"Ashraf S","family":"Habib","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology","place":["Durham, USA"]},{"name":"Division of Women's Anesthesia","place":["Durham, USA"]},{"name":"Duke University Medical Center Box 3094","place":["Durham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S144066"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2021.673962"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2012.03.009"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.860019"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1054\/jpai.2002.123652"},{"key":"e_1_3_4_8_1","unstructured":"Center for Disease Control and Prevention NC for HS. Data Access - Vital Statistics Online. 2022. Available from: https:\/\/www.cdc.gov\/nchs\/data_access\/vitalstatsonline.htm#Mortality_Multiple"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001939"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12282"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9592.2008.02764.x"},{"key":"e_1_3_4_12_1","article-title":"Nonsteroidal anti-inflammatory drugs (NSAIDs)","author":"Ghlichloo I","year":"2023","unstructured":"Ghlichloo I, Gerriets V. Nonsteroidal anti-inflammatory drugs (NSAIDs). StatPearls. 2023. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547742\/","journal-title":"StatPearls."},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2017.0898"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/2049463720912496"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2008.01800.x"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(00)01570-1"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-00415-2"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15327"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1039\/D2MD00081D"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1152\/jn.2001.86.2.629"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(01)00391-8"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1216080109"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2022.933874"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-019-06931-8"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvy152"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12378"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2019.06.014"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2189"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13215"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-016-1231-9"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0611364104"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnab032"},{"key":"e_1_3_4_33_1","unstructured":"Vertex Pharmaceuticals Incorporated. Vertex Announces Positive Phase 2 Data in Third Proof-of-Concept Study with the NaV1.8 Inhibitor VX-150. 2018. Available from: https:\/\/news.vrtx.com\/news-releases\/news-release-details\/vertex-announces-positive-phase-2-data-third-proof-concept-study"},{"key":"e_1_3_4_34_1","unstructured":"Vertex Pharmaceuticals Incorporated. Vertex Announces Treatment with the NaV1.8 Inhibitor VX-150 Showed Significant Relief of Acute Pain in Phase 2 Study. 2018. Available from: https:\/\/news.vrtx.com\/news-releases\/news-release-details\/vertex-announces-treatment-nav18-inhibitor-vx-150-showed"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209870"},{"key":"e_1_3_4_36_1","unstructured":"Vertex Pharmaceuticals Incorporated. Study Details | Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy Participants | ClinicalTrials.gov. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05635110?intr=VX-548&page=2&rank=13"},{"key":"e_1_3_4_37_1","unstructured":"Vertex Pharmaceuticals Incorporated. Study Details | A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548 Midazolam and Digoxin | ClinicalTrials.gov. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05541471?intr=VX-548&page=2&rank=14"},{"key":"e_1_3_4_38_1","unstructured":"Vertex Pharmaceuticals Incorporated. Study Details | A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548 | ClinicalTrials.gov. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05455502?intr=VX-548&page=1&rank=1"},{"key":"e_1_3_4_39_1","unstructured":"Vertex Pharmaceuticals Incorporated. Study Details | A Study to Evaluate the Effect of Food on the Pharmacokinetics of VX-548 | ClinicalTrials.gov. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05851157?intr=VX-548&rank=8"},{"key":"e_1_3_4_40_1","unstructured":"Vertex Pharmaceuticals Incorporated. Study Details | A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine | ClinicalTrials.gov. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06336096?intr=VX-548&page=2&rank=16"},{"key":"e_1_3_4_41_1","unstructured":"Vertex Pharmaceuticals Incorporated. Study Details | Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment | ClinicalTrials.gov. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05704556?intr=VX-548&page=1&rank=4"},{"key":"e_1_3_4_42_1","unstructured":"Vertex Pharmaceuticals Incorporated. Study Details | Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Mild or Moderate Hepatic Impairment | ClinicalTrials.gov. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05560464?intr=VX-548&rank=5"},{"key":"e_1_3_4_43_1","unstructured":"Vertex Pharmaceuticals Incorporated. VX-548 Phase 3 Results in Acute Pain. 2024. Available from: https:\/\/investors.vrtx.com\/static-files\/2b8b5989-a5ff-456a-8bf7-1709028d5f20"},{"key":"e_1_3_4_44_1","first-page":"401","article-title":"Selective Inhibition of NaV1.8 with VX-548 for Acute Pain","volume":"789","author":"Jones J","year":"2023","unstructured":"Jones J, Corral DJ, Lechner SM, et al. Selective Inhibition of NaV1.8 with VX-548 for Acute Pain. N Engl J Med. 2023;789:401.","journal-title":"N Engl J Med."},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-024-00029-z"},{"key":"e_1_3_4_46_1","unstructured":"BusinessWire Vertex Pharmaceuticals Incorporated. Vertex Announces Positive Results from the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain. https:\/\/www.businesswire.com\/news\/home\/20240129843577\/en\/"},{"key":"e_1_3_4_47_1","unstructured":"Vertex Pharmaceuticals Incorporated. VX-548 Phase 2 Results in Painful Diabetic Peripheral Neuropathy. 2023. Available from: https:\/\/investors.vrtx.com\/static-files\/1eeed94f-d3fe-42f6-9557-2e71475afc35"},{"key":"e_1_3_4_48_1","unstructured":"Vertex Pharmaceuticals Incorporated. Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain. 2024. Available from: https:\/\/investors.vrtx.com\/news-releases\/news-release-details\/vertex-announces-fda-acceptance-new-drug-application-suzetrigine"},{"key":"e_1_3_4_49_1","unstructured":"Vertex Pharmaceuticals Incorporated. Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain. 2024. Available from: https:\/\/investors.vrtx.com\/node\/31996\/pdf"}],"container-title":["Pain Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17581869.2024.2421749","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T03:35:18Z","timestamp":1739244918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17581869.2024.2421749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1080\/17581869.2024.2421749"],"URL":"https:\/\/doi.org\/10.1080\/17581869.2024.2421749","relation":{},"ISSN":["1758-1869","1758-1877"],"issn-type":[{"value":"1758-1869","type":"print"},{"value":"1758-1877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipmt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipmt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-09-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}